{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"See the adverse event tables for specifics.","groups":[{"description":"Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Antiangiogenesis Therapy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Approximately 1 year","title":"Number of Participants Who Experienced Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0","type":"PRIMARY","unitOfMeasure":"Participants experiencing adverse events"}